内容紹介
近年リピオドールとゼラチンスポンジを用いる肝動脈化学塞栓療法(conventional transcatheter arterial chemoembolization:cTACE)の治療効果と安全性が正しく理解され、cTACEが手術不能な肝細胞癌に対する標準治療となりつつある。TACE支援ソフトと優れた細径マイクロカテーテルの登場により、2017年には小肝癌に対する経動脈的アブレーション(transcatheter arterial ablation:TAA)がトレンドとなる可能性がある。
Since the therapeutic efficacy and safety of conventional transcatheter arterial chemoembolization (cTACE) with Lipiodol and gelatin sponge particles have been correctly recognized, cTACE is considered as a standard treatment option for unresectable hepatocellular carcinoma (HCC). With advances in TACEguidance software and thin microcatheter-guidewire systems, transcatheter arterial ablation (TAA) for small HCC may become a new trend in 2017.
目次
Since the therapeutic efficacy and safety of conventional transcatheter arterial chemoembolization (cTACE) with Lipiodol and gelatin sponge particles have been correctly recognized, cTACE is considered as a standard treatment option for unresectable hepatocellular carcinoma (HCC). With advances in TACEguidance software and thin microcatheter-guidewire systems, transcatheter arterial ablation (TAA) for small HCC may become a new trend in 2017.